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SUMMARY
Background. Assessing bronchial hyper-responsiveness (BHR)
is a main diagnostic criterion of asthma. Provocation testing is
not readily available in general practice, but peak expiratory
flow (PEF) is. Several guidelines promote the use of PEF vari-
ability as a diagnostic tool for BHR. This study tested the agree-
ment between histamine challenge testing and PEF variability,
and the consequences for diagnosing asthma
Aim. To investigate the possibility of assessing BHR by PEF
variability, using a histamine provocation test as a reference.
Method. Subjects with signs or symptoms indicating asthma
(persistent or recurrent respiratory symptoms or signs of
reversible bronchial obstruction) (n = 323) were studied. They
had been identified in a population screening for asthma. A hist-
amine provocation test and PEF variability were assessed over
a three-week period. Asthma was defined as signs or symptoms
together with a reversible airflow obstruction or BHR to the hist-
amine challenge test. BHR was defined as a PC20 histamine of
X8 mg/ml or a PEF variability of 15%. Overall correlation
between PC20 and PEF variability was calculated using
Spearman’s rho. Furthermore, a decision tree was constructed
to clarify the role of BHR in diagnosing asthma.
Results. Thirty-two patients had a reversibility in forced expira-
tory volume in 1 second (FEV1) of 9% predicted, 131 patients
showed a PC20 of X8 and 11 patients had a PEF variability of
15%. Overall correlation was poor at only –0.27 (P<0.0001).
One hundred and fourteen of the 131 patients diagnosed as
having asthma when the histamine challenge test was used
were not diagnosed by PEF variability.
Conclusion. PEF variability cannot replace bronchial provoca-
tion testing in assessing BHR. This indicates that PEF variability
and bronchial provocation do not measure the same aspects of
BHR. If BHR testing is required in diagnosing asthma, a
bronchial provocation test has to be used in general practice as
well.
Keywords: asthma diagnosis, peak flow, bronchial hyper-
responsiveness.
Introduction
ASTHMA is a common disease in general practice, for whicha pathognomonic test is lacking. At this moment, diagnosis
of asthma by a general practitioner (GP) is based on a positive
history of bronchial symptoms, atopic disease(s), occupational
exposure to known sensitizing agents, and the findings at a phys-
ical examination.1-3 GPs usually diagnose asthma on the basis of
symptoms only, without the use of additional testing, such as
spirometry or allergy testing. This may be one of the reasons that
patients remain unrecognized — ‘underdiagnosis’ that leads to
‘undertreatment’ or a delay in treatment1,3 — and might be an
explanation for the increase in asthma morbidity.4,5 As asthma is
characterized by reversible airflow obstruction, BHR, and
inflammation of the bronchial tubes, spirometry can confirm
both the reversible airflow obstruction and the hyper-responsive-
ness.6 Additional use of spirometry can facilitate the interpreta-
tion of symptoms and the identification of asthma from the com-
monly presented respiratory symptoms in general practice.
Bronchial obstruction, one of the cornerstones of asthma diagno-
sis, is easy to assess. However, it might be absent at the time of
testing.7 Therefore, assessment of BHR is also proposed in the
diagnosis of asthma.6,8 Its assessment is considered to be a main
diagnostic criterion2,9 to distinguish between healthy subjects and
subjects with respiratory diseases,10 although there is conflicting
evidence in this respect,11 probably arising from variation in the
population studied.10
BHR can be assessed by bronchial provocation testing or by
measuring PEF variability.12-14 This paper will focus on the value
of PEF variability in assessing BHR. Chest physicians usually
test BHR by a provocation test, not only as a diagnostic routine,
but also as an indicator for adjusting or readjusting medication.9
For the majority of asthma patients treated by GPs, BHR testing
is quite an exception, as bronchial provocation would require
easy access to a lung function laboratory. However, in general
practice, PEF measurement has already established its place for
measuring bronchial obstruction.7 When the PEF is measured at
least twice daily, the PEF variability, which reflects the degree of
bronchial responsiveness, can be calculated as well.15 This
assessment requires only low technology: the five ‘Ps’ of patient,
PEF meter, pocket calculator, pencil, and paper. In this way, ade-
quate diagnosis of asthma might be within reach of general prac-
tice (Figure 1).
PEF variability measures the variation in airway calibre under
everyday life or work conditions, and PC20 measures changes in
bronchial calibre under standardized challenge. Several studies
have been performed on the correlation between PC20 and PEF
variability,12,16,17 but there remains controversy over their find-
ings. Asthma medication might interfere with both PEF and PC20
measurements,17 and the use of medication might have been a
factor interfering with the results of these studies. It was for this
reason that we carried out a study on patients without a previous
asthma diagnosis,18 which has been described only once before
in a random sample from a general practice population.19 This
study was carried out to determine if PC20 histamine can be
replaced by PEF variability. It assessed histamine bronchial
provocation testing and the PEF variability of subjects with signs
or symptoms indicating asthma. Our hypothesis was that a peak
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flow variability of 15% is as successful in assessing BHR as
PC20 histamine. If true, mapping BHR in general practice would
be possible this way.
Method
Design
In this explanatory study, PEF variability and PC20 histamine
were compared in 323 subjects reporting signs or symptoms of
asthma in a population screening for asthma.18
Subjects
Patients were recruited from a screening for asthma in an open
population. A total of 1155 randomly selected subjects were
screened. The selection procedure has been described extensively
elsewhere.18 In summary, all subjects were adults between 25
and 70 years old, recruited from the patients of 10 general prac-
tices. Included in this study were subjects with one or more of
the signs or symptoms indicating asthma (Table 1).20 Excluded
were those who were unable to use a PEF device or to complete
a diary.
Asthma definition
To diagnose asthma, we used an adapted version of the algorithm
of Sheffer et al (Figure 1).6 All our subjects had a bronchoprovo-
cation test and a three-week monitoring of their PEF. Asthma
was defined as symptoms and a reversibility after bronchodila-
tion with 800 mg of salbutamol of at least 9% predicted7 or
BHR, i.e. a PC20 of X8 mg/ml.9
Measurement scheme
All subjects eligible for study were visited and instructed at
home by five trained investigators. After three weeks of measur-
ing PEF twice a day, they were invited to a lung function labora-
tory.
Questionnaire
Subjects were screened using an asthma questionnaire extended
with questions of specific and non-specific BHR and smoking
history.20 Data were collected by five trained investigators.
Diary and PEF measurement
All patients were visited at home and trained in how to perform
and to use a mini-Wright peak flow meter, and how to register
PEF in a diary. They recorded their PEF for three weeks, twice a
day at the same time in the morning and in the evening. For
analysis, the highest value of three measurements was taken. The
diurnal PEF index was calculated as:21
In order to test for learning effects, the mean morning PEF val-
ues on days 1–7 were first compared with the mean morning val-
ues on days 8–21. Since this showed no significant difference
(P>0.2, paired t-test), measurements for the total period of 21
days were used for analysis. For analysis, the mean diurnal PEF
index was calculated by taking the arithmetic mean of 21 daily
PEF variabilities.
Spirometry
FVC and FEV1 were assessed by means of an integrating
flowmeter (Microspiro HI-298, Chest Corporation, Japan),
according to the standards of the European Respiratory Society
(ERS).9,22 Reversibility was assessed 15 min after administration
of 800 mg of salbutamol inhaled by means of a spacer, and
expressed as percentage predicted.7,23,24
Bronchial provocation testing
At the University Lung Center, Dekkerswald, lung function mea-
surement was carried out during an exacerbation-free period.
Twelve hours before lung function testing, no bronchodilator
was used. Trained lung function technicians measured FVC,
FEV1, and bronchial responsiveness to histamine (PC20 histamine
values) by means of the Microspiro HI-298 according to ERS
standards.9 Bronchial provocation with histamine (PC20) was
assessed according to Cockcroft and Hargreave.10 The provoca-
tional concentration of histamine causing a 20% fall in FEV1
from the baseline value (PC20) was calculated by linear interpola-
tion of the difference in FEV1 versus 2log PC20. Challenging
started with saline and subsequent increases in histamine from a
dose of 0.030 up to a concentration of 32 mg/ml.25
Analysis
Overall correlation between PC20 and PEF variability was calcu-
lated with Spearman’s rho. Differences between groups were
tested using Student’s t-test or chi-square statistics as appropri-
ate. As significance level, P X0.05 (two-tailed) was used.
In a second analysis, the diagnostic properties of PEF variabi-
lity were compared with PC20. For this analysis, a decision tree
was used. In the first step, all subjects were included with signs
or symptoms. In the second step, reversible bronchial obstruction
on testing was included. If subjects did meet this criterion, the
diagnosis of ‘asthma’ was established, which concluded diagnos-
tic testing. For all other subjects, BHR testing was introduced as
the third step, and all subjects with a positive test result were
considered asthmatic. This step was first analysed using the hist-
amine challenge test result followed by diagnostic allocation
when PEF replaced the histamine challenge. PEF-related classifi-
cation was compared for correctness with the standard histamine
challenge-based diagnosis.
To examine the influence of the cut-off point of PEF variabili-
ty, a series of tables was produced to show the influence of the
cut-off point of a PEF variability on the test characteristics
(Table 2).
This study was approved by the ethics committee of the
University Lung Center, Dekkerswald. All participants gave
informed consent.
Results
On screening, 529 subjects had signs or symptoms that could
indicate asthma. Of these, 323 met the inclusion criteria and were
willing to participate (Table 3). Non-participants (n = 206) did
not differ significantly in age, smoking habits or FEV1% predict-
ed, but showed a lower reversibility of FEV1 after bronchodila-
tion (2.89% versus 4.05%, P = 0.002) compared with the partici-
pants (Table 3). All 323 subjects were able to perform PEF mea-
surement and to complete a diary. Five incomplete patient PEF
diaries could not be evaluated and had to be excluded from the
analysis. The overall correlation between PC20 and PEF variability
was –0.27 (P < 0.0001).
In the second part of the analysis, the decision tree was fol-
lowed (Figure 2). In the first step, reversible bronchial obstruc-
tion of FEV1 of  9% predicted was included, which was present
PEFvariability = 
PEFhighest – PEFlowest 
x 100%
PEFmean
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in 32 subjects, leading to the diagnosis ‘asthma’. Analysis of
BHR in this part of the tree is not further discussed, as its diag-
nostic testing in this group would be spurious.
The second step showed that, of the group of 291 patients
with respiratory symptoms but without a reversible airflow
obstruction, 111 had a PC20 of X8 mg/ml leading to the diagno-
sis ‘asthma’. The third step showed that, if a PEF variability of
 15% was used for BHR instead of bronchial provocation test-
ing, only nine of these 111 cases would have been diagnosed.
Inclusion of PEF would have resulted in an overall frequency of
asthma of 0.13 (32 with a reversible airflow obstruction and
nine with a PEF variability of 15% = 41/318) instead of 0.45
(143/318).
As shown in Table 2, the cut-off point of PEF variability
influenced the test characteristics: with a variability of  4.56%,
the discrimination between subjects diagnosed with ‘asthma’ on
the basis of a PC20 histamine of X8 mg/ml proved to be optimal,
but a substantial number of cases would still have been incor-
rectly classified.
Discussion
This study investigated the assessment of BHR in a general prac-
tice population of subjects with a risk of asthma using a hista-
mine provocation test and PEF variability. It was concluded that
the correlation between PC20 histamine and PEF variability was
low, and using PEF instead of PC20 histamine did lead to a sub-
stantially lower diagnostic classification. Therefore, PEF could
not be recommended as a substitute for the PC20 histamine. So,
our hypothesis that a PEF variability of  15% is as successful in
assessing BHR as PC20 histamine does not hold, and this implies
that PEF variability cannot replace the PC20 histamine provoca-
tion test. This requires a reconsideration of the diagnostic role of
PEF, as advocated in various guidelines.1,9
Other studies have reported correlations between PEF and
PC20 histamine of –0.40 to –0.50.12,17 These studies were carried
out with patients with an established diagnosis of asthma. For
Table 1. Questions used to determine subjects with a higher risk of
asthma.21
Subjects were asked if they suffered from
– chronic cough on most days or nights in three consecutive
months
– chronic phlegm production on most days or nights in three con-
secutive months
– more than one period of at least three weeks of cough or phlegm
production in the previous three years
– dyspnoea when going upstairs or walking fast on level ground
– regular chest wheezing or whistling
– attacks of dyspnoea with wheezing (asthmatic attacks)
– ‘allergic dyspnoea’ after contact with dust, cats, dogs, etc.
– ‘non-allergic dyspnoea’ after exercise or contact with cold air, cig-
arette smoke, etc.
Table 2. Relation between PC20 and PEFR variability and test specifications using a cut off point of 5%, 10% and 15%.
PC20  8 mg/ml PC20 > 8 mg/ml Total
PEFR  5% 73 58 131
PEFR < 5% 57 130 187
PEFR  10% 18 8 26
PEFR < 10% 112 180 292
PEFR  15% 6 4 10
PEFR < 15% 124 184 308
Total 130 188 318
Test specifications
PEFR 5% 10% 15%
Sensitivity 73/130 = 0.56 18/130 = 0.14 6/130 = 0.05
Specificity 130/188 = 0.69 180/188 = 0.96 184/188 = 0.97
PPVa for PEF 73/131 = 0.56 18/26 = 0.69 6/10 = 0.60
NPVb for PEF< 130/187 = 0.66 180/292 = 0.62 184/308 = 0.60
Table 3. Clinical characteristics.
Participants Non-participants P value
(n = 323) (n = 206)
Male/female 135/188 73/133 NS
Age (years) 43±12 44±13 NS
FEV1 (% predicted) 95±16 93±15 NS
FEV1 (ml) 3154±800 3008±857 <0.05
Reversibility (% predicted) 4±5 3±4 <0.05
PC20 7.3 Not available –
Smoking status
(Ex)smokers/never smokers 129/194 96/110 0.131
Pack–years 8±10 10±11 0.183
Mean values ± SD except for PC20 where the geometric mean is given of participants only.
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Figure 1. Algorithm for diagnosing asthma. Asthma is characterized by reversible airflow obstruction and can often be diagnosed with complete cer-
tainty. However, when mixed signals are present clinically, one must consider other diseases that can also cause airflow obstruction. Sometimes, it
may be impossible to distinguish among several possibilities or there may actually be coexisting diseases. This disclaimer is, in essence, true with
any diagnosis. The general approach in diagnosing asthma is first to determine whether the patient has symptoms of cough, wheezing, shortness of
breath or exercise intolerance. Do the symptoms appear to be episodic in nature? If so, a diagnosis of asthma should be strongly considered, and
efforts should be made to demonstrate the reversibility of airflow obstruction after treatment using pulmonary function tests. If airflow obstruction is
present but cannot be immediately reversed with an inhaled bronchodilator, it may be necessary to treat the patient aggressively with bronchodila-
tors and anti-inflammatory agents for up to six weeks before deciding that airflow obstruction is truly irreversible. If the symptoms present suggest
asthma but there is no evidence of airflow obstruction, a bronchoprovocation test should be performed. If the bronchial challenge is positive, then
once again a diagnosis of asthma should be strongly considered. At the point of considering asthma strongly, one should consider other causes of
reversible airflow obstruction, such as heart disease, the presence of foreign bodies in airways, and chronic obstructive pulmonary disease with a
reversible component. If such diseases are present, and there are many to consider, one must try to determine whether this disease is predominant
or whether asthma also coexists. When there is more than one disease present that can cause airflow obstruction, a conclusive diagnosis is difficult.
Modifying factors that increase the probability of asthma include a personal or family history of asthma, hay fever or other allergies. It should be
remembered at this point, however, that there are two ages of onset of asthma. Asthma that begins in childhood is almost always associated with a
strong history of allergy and is likely to be atopic. One final consideration is that some patients with severe, longstanding and poorly treated asthma
may develop irreversible airflow obstruction. These patients may still deserve a diagnosis of asthma if all other factors lead to that diagnosis, and if
no other good cause for the airflow obstruction is found.
Start
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Results
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this group, the question as to whether PC20 can be replaced by
PEF variability as a diagnostic tool is less relevant. This question
is particularly relevant for subjects with signs or symptoms sus-
picious of asthma but without an established diagnosis. Trigg et
al19 studied subjects from general practice with and without res-
piratory symptoms, and found figures similar to our results. A
possible explanation of the low correlation might be the subclini-
cal form of the disease in both Trigg et al’s study19 and our pop-
ulation.
Another explanation is related to the method applied to
express peak flow variation. We used the arithmetic mean of
PEF measurements over a three-week period in our correlation,
and this might disguise clinically relevant high PEF variability
for only a few days. Therefore, the correlation between the num-
ber of days of a PEF variability of  15% and PC20 histamine
was also assessed. However, this did not essentially change the
outcome (r = –0.26). More frequent measurement, e.g. four times
a day, would probably have increased the PEF variability,13 but it
is very unlikely that this would have increased the correlation
substantially. From our analysis, it became clear that with a PEF
variability of 15% the sensitivity is almost zero, and thus not
very applicable for use in everyday practice. A decrease in the
PEF variability would increase the sensitivity, but then the values
come so close to normal variability that the findings would lack
any specificity.
BHR assessment generally refers to PC20 histamine assessing
BHR. When this is the case, PEF variability cannot replace this.
The use of PEF measurements in general practice should be
reserved for assessing reversibility.7 The practical implication of
this is that BHR testing would require access to a function labo-
ratory. Although it is possible to perform a provocation test at the
surgery,26 testing in a laboratory setting is preferred for reasons
of safety and technical quality of the test performance.
In conclusion, the results of this study suggest that PEF cannot
replace PC20 in testing BHR for the diagnosis of asthma. Where
BHR is used as an inclusion criterion for asthma it should be
tested by the PC20. This has consequences for the possibility of
diagnosing asthma in primary care, where there is no easy access
to a histamine challenge test.
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